Should fluoxetine be discontinued during pregnancy?

Should Fluoxetine Be Stopped in Pregnant Patients?

Fluoxetine should NOT be routinely discontinued in pregnant patients, particularly in women with moderate-to-severe depression, history of severe depression, previous relapse upon discontinuation, or inadequate response to psychotherapy. The decision must be individualized based on depression severity, treatment history, and relapse risk, as untreated maternal depression poses significant risks to both mother and fetus 1.

Evidence-Based Decision Framework

When to CONTINUE Fluoxetine During Pregnancy

Based on American Psychiatric Association and American College of Obstetricians and Gynecologists recommendations 1, fluoxetine should be continued in:

• Women with severe or recurrent depression who have previously relapsed when discontinuing antidepressants (relapse risk increases 2.3-fold with discontinuation) 2
• History of severe suicide attempts or severe depression with documented response to fluoxetine
• Inadequate response to psychotherapy or when psychotherapy is not feasible
• Moderate-to-severe depression that has not improved within 2 weeks of non-pharmacological interventions 1

When Discontinuation May Be Considered

• Mild depression with recent onset (≤2 weeks) that responds to monitoring, exercise, and social support 1
• Mild depression in women without history of severe episodes or relapse upon discontinuation

Safety Profile: Reassuring Evidence

Neurodevelopmental Outcomes

The most robust evidence indicates that fluoxetine does not substantially increase risk of autism spectrum disorder (ASD) or ADHD 1. High-quality sibling-control studies (which best control for maternal depression confounding) show that most previously reported associations disappear when comparing exposed versus unexposed siblings 3.

Cardiac Malformations

While some studies suggest a slight increase in cardiovascular malformations (RR 1.36-1.6), the absolute risk remains small 4, 5. Importantly, this association may reflect ascertainment bias rather than true causation, as similar risks appear in depressed women who deferred SSRI therapy 5. The FDA label notes fluoxetine crosses the placenta but should be used when potential benefit justifies potential risk 6.

Neonatal Adaptation Syndrome

Third-trimester exposure may cause transient neonatal complications (respiratory distress, jitteriness, feeding difficulties) requiring monitoring but typically resolving without long-term sequelae 6. There is a potential increased risk of persistent pulmonary hypertension of the newborn (PPHN), though evidence is limited 6.

Risks of Untreated Depression

Discontinuing treatment carries substantial maternal risks 7:

• Increased gestational diabetes
• Worsened pregnancy depression
• Higher postpartum depression rates
• Decreased breast milk production
• Relapse of major depression (particularly in severe/recurrent cases) 2

Women who discontinued antidepressants during pregnancy were more likely to experience relapse than those who continued treatment 6.

Clinical Algorithm

1. Assess depression severity and history:

   • Mild, recent-onset (≤2 weeks): Monitor, encourage exercise/social support
   • Moderate-to-severe OR no improvement after 2 weeks: Continue/initiate treatment

2. Evaluate relapse risk factors:

   • Previous relapse upon discontinuation → CONTINUE
   • Severe depression history or suicide attempts → CONTINUE
   • Failed psychotherapy trials → CONTINUE

3. Third trimester considerations:

   • Carefully weigh risks/benefits 6
   • Prepare neonatal team for potential adaptation syndrome
   • Monitor infant for 48-72 hours post-delivery

4. Avoid abrupt discontinuation:

   • Risk of maternal relapse outweighs fetal concerns in most cases 1
   • Fluoxetine's long half-life provides some protection against withdrawal

Critical Pitfalls to Avoid

• Do not discontinue based solely on pregnancy status in women with established benefit from fluoxetine
• Do not switch medications unnecessarily during pregnancy in stable patients (per NICE guidance referenced in 8)
• Do not underestimate maternal depression risks - untreated depression has documented adverse pregnancy outcomes 7
• Ensure proper neonatal monitoring if continued through third trimester to address potential adaptation syndrome 6

The evidence strongly supports that the risks of untreated maternal depression typically outweigh the small potential fetal risks of fluoxetine continuation in most clinical scenarios 1, 3.